Clostridioides difficile Archives
NIH grant launches C. diff vaccine research initiative
Mar. 30, 2023—Vanderbilt has received an NIH grant to launch the Vanderbilt Antibody and Antigen Discovery for Clostridioides difficile Vaccines, or VANDy-CdV.
C. diff infections drop in children
Nov. 3, 2022—The number of pediatric infections caused by Clostridioides difficile (C. diff) decreased from 2013 to 2019, likely due to an increase in antibiotic stewardship programs and improved hospital contact protocols, Vanderbilt researchers found.
C. difficile may contribute to colorectal cancer: study
Jul. 28, 2022—A Vanderbilt study found that the bacterium Clostridioides difficile (C. difficile) may be a previously unrecognized contributor to colorectal cancer.
Molecular imaging of C. diff infection
Sep. 30, 2021—C. difficile — the leading cause of hospital-associated intestinal infections — induces a rapid influx of bile acids into the gut, which could provide a novel target for blocking infection.
C. diff captures blood cell cofactor to build defensive shield
Jun. 10, 2020—Vanderbilt University Medical Center scientists have identified a C. diff protein system that senses and captures heme (part of hemoglobin) to build a protective shield that fends off threats from our immune system and antibiotics.
Structural views of a C. diff toxin
Jan. 10, 2020—D. Borden Lacy and colleagues used cryo-electron microscopy to define the structure of a C. diff toxin, providing a framework for the design of novel therapeutics.
Wexler receives Helen Hay Whitney Foundation Fellowship
Dec. 12, 2019—Aaron Wexler, PhD, a research fellow in the Department of Pathology, Microbiology and Immunology, has received a Helen Hay Whitney Foundation Fellowship.
Treating C. diff: new purpose for an old drug?
Sep. 24, 2019—An inexpensive generic drug once used to prevent gastrointestinal ulcers in people taking daily NSAIDs protects against C. diff infection in mice.
